¼¼°èÀÇ Ç¥ÇÇ ¼ºÀå ÀÎÀÚ ¼ö¿ëü(EGFR) ¾ïÁ¦Á¦ ½ÃÀå(2025-2029³â)
Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2025-2029
»óǰÄÚµå : 1645484
¸®¼­Ä¡»ç : TechNavio
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 203 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,500 £Ü 3,584,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,000 £Ü 5,734,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ç¥ÇÇ ¼ºÀå ÀÎÀÚ ¼ö¿ëü(EGFR) ¾ïÁ¦Á¦ ½ÃÀåÀº 2024-2029³â°£ 107¾ï 3,250¸¸ ´Þ·¯ È®´ëµÇ°í, ¿¹Ãø ±â°£ µ¿¾È 10.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. Ç¥ÇÇ ¼ºÀå ÀÎÀÚ ¼ö¿ëü(EGFR) ¾ïÁ¦Á¦(EGFR) ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¿¡ ´ëÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

ÇöÀçÀÇ ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ¼ºÀå¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº ÁÖ¿ä ¾Ï ÀûÀÀÁõ¿¡ ´ëÇÑ À¯º´·ü Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ Àνİú µµÀÔ Áõ°¡, ±â¼ú ¹× ¿¬±¸ ¹ßÀüÀ¸·Î ÀÎÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ 2025³â
Á¾·á ¿¬µµ 2029³â
¿¹Ãø ±â°£ 2025-2029³â
¼ºÀå ¸ð¸àÅÒ °¡¼Ó
Àü³â ´ëºñ(2025³â) 9.4%
CAGR 10.5%
ÁõºÐ ±Ý¾× 107¾ï 3,250¸¸ ´Þ·¯

ÀÌ º¸°í¼­´Â ÇâÈÄ ¸î ³âµ¿¾È Ç¥ÇÇ ¼ºÀå ÀÎÀÚ ¼ö¿ëü(EGFR) ¾ïÁ¦Á¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î ´Ù¾çÇÑ À¯ÇüÀÇ ¾ÏÀ» Ä¡·áÇϱâ À§ÇÑ ¿¬±¸ ºÎ¹® Áõ°¡¸¦ ²Å¾Ò½À´Ï´Ù. ¶ÇÇÑ, ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎ Áõ°¡¿Í »óȯ ÇÁ·Î±×·¥ Áõ°¡´Â ½ÃÀåÀÇ Å« ¼ö¿ä·Î À̾îÁú °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå Technavio ºÐ¼®

Á¦3Àå ½ÃÀå ±¸µµ

Á¦4Àå ½ÃÀå ±Ô¸ð

Á¦5Àå ½ÃÀå ±Ô¸ð ½ÇÀû

Á¦6Àå Á¤¼º ºÐ¼®

Á¦7Àå Five Forces ºÐ¼®

Á¦8Àå ½ÃÀå ¼¼ºÐÈ­ : ÀûÀÀÁõº°

Á¦9Àå ½ÃÀå ¼¼ºÐÈ­ : À¯Åë ä³Îº°

Á¦10Àå °í°´ »óȲ

Á¦11Àå Áö¿ªº° »óȲ

Á¦12Àå ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ ¹× ¼ºÀå ¾ïÁ¦¿äÀÎ

Á¦13Àå °æÀï ±¸µµ

Á¦14Àå °æÀï ºÐ¼®

Á¦15Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The epidermal growth factor receptor (EGFR) inhibitors market is forecasted to grow by USD 10732.5 mn during 2024-2029, accelerating at a CAGR of 10.5% during the forecast period. The report on the epidermal growth factor receptor (EGFR) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in the prevalence of major cancer indications, increasing awareness and adoption of personalized medicine, and advancements in technology and research.

Market Scope
Base Year2025
End Year2029
Series Year2025-2029
Growth MomentumAccelerate
YOY 20259.4%
CAGR10.5%
Incremental Value$10732.5 mn

Technavio's epidermal growth factor receptor (EGFR) inhibitors market is segmented as below:

By Indication

By Distribution Channel

By Geographical Landscape

This study identifies the increase in research areas for treatment of various types of cancer as one of the prime reasons driving the epidermal growth factor receptor (EGFR) inhibitors market growth during the next few years. Also, rise in number of drug pipelines and increasing reimbursement programs will lead to sizable demand in the market.

The report on the epidermal growth factor receptor (EGFR) inhibitors market covers the following areas:

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epidermal growth factor receptor (EGFR) inhibitors market vendors that include Amgen Inc., ASSERTIO HOLDINGS INC., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Checkpoint Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Hansoh Pharmaceutical Group Co. Ltd., Hutchison China Meditech Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson Inc., Lutris Pharma, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Puma Biotechnology Inc., and Takeda Pharmaceutical Co. Ltd.. Also, the epidermal growth factor receptor (EGFR) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

2 Technavio Analysis

3 Market Landscape

4 Market Sizing

5 Historic Market Size

6 Qualitative Analysis

7 Five Forces Analysis

8 Market Segmentation by Indication

9 Market Segmentation by Distribution Channel

10 Customer Landscape

11 Geographic Landscape

12 Drivers, Challenges, and Opportunity/Restraints

13 Competitive Landscape

14 Competitive Analysis

15 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â